Immunotherapy for Cancer in India
Get Immunotherapy for Cancer at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Immunotherapy for Cancer in UAE
Immunotherapy for Cancer at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Cancer immunotherapy harnesses the body's own immune system to identify, attack, and eliminate malignant cells — representing one of the most significant paradigm shifts in oncology over the past two decades. Depending on cancer type and stage, modern immunotherapy protocols achieve durable response rates of 20–45% in previously refractory cancers, with some hematologic malignancies showing complete remission rates exceeding 80% with CAR-T cell therapy. International patients choose GAF Healthcare to access world-class oncology centers in India and the UAE, where JCI- and NABH/DHA-accredited hospitals deliver cutting-edge checkpoint inhibitor regimens, adoptive cell therapies, and bispecific antibody protocols at costs that are 40–70% lower than equivalent treatment in the United States, the United Kingdom, or Western Europe.
Hospital Stay: 3–7 days per treatment cycle (outpatient infusions are common; inpatient admission required for CAR-T cell therapy and high-grade immune-related adverse events) • Total Stay in Country (Fit-to-Fly): 2–6 weeks minimum before international travel is medically cleared; CAR-T recipients typically require 4–8 weeks of local monitoring post-infusion • Success Rate: Objective response rates range from 15–45% for solid tumors with PD-1/PD-L1 checkpoint inhibitors; 70–85% complete remission rates reported for relapsed/refractory B-cell lymphoma with CAR-T (axicabtagene ciloleucel / tisagenlecleucel); outcomes are highly cancer-type and biomarker dependent
What Is It?
Cancer immunotherapy is a class of treatments that modulates or augments the immune system's capacity to recognize tumor-associated antigens (TAAs) and mount a sustained cytotoxic response against malignant cells. Unlike conventional chemotherapy — which exerts cytotoxic effects on all rapidly dividing cells — immunotherapy is designed to achieve tumor-selective killing while generating immunological memory capable of preventing relapse. The principal biological targets include immune checkpoint proteins (PD-1, PD-L1, CTLA-4, LAG-3, TIM-3), tumor-infiltrating lymphocyte (TIL) pathways, and surface antigens uniquely expressed on cancer cells such as CD19, CD20, HER2, and EGFR. Understanding which pathway to target requires comprehensive molecular tumor profiling, making precision diagnostics an inseparable component of modern immunotherapy.
The tumor microenvironment (TME) plays a central role in immune evasion. Malignant cells upregulate checkpoint ligands (e.g., PD-L1) that bind to inhibitory receptors on cytotoxic T lymphocytes (CTLs), effectively silencing anti-tumor immunity. Checkpoint inhibitors such as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) block these interactions, restoring T-cell activation. Simultaneously, strategies such as chimeric antigen receptor T-cell (CAR-T) therapy engineer the patient's own lymphocytes ex vivo to express high-affinity receptors targeting tumor-specific antigens, achieving direct cytolytic activity independent of MHC-I presentation — a mechanism tumors frequently exploit to escape conventional immune surveillance.
The current standard of care integrates immunotherapy into multimodal oncology protocols. For non-small cell lung cancer (NSCLC) with high PD-L1 expression (TPS ≥50%), first-line pembrolizumab monotherapy is now preferred over platinum-doublet chemotherapy. For metastatic melanoma, dual checkpoint blockade (nivolumab + ipilimumab) demonstrates 5-year overall survival rates of approximately 52%. Tumor mutational burden (TMB-H ≥10 mutations/megabase) and microsatellite instability-high (MSI-H) status serve as pan-tumor predictive biomarkers for checkpoint inhibitor responsiveness, as recognized by FDA tissue-agnostic approvals for pembrolizumab and dostarlimab. Treatment selection demands multidisciplinary tumor board review encompassing medical oncology, molecular pathology, radiology, and — where indicated — radiation oncology.
Candidates
• ELIGIBILITY CRITERIA:
• Patients with histologically or cytologically confirmed solid tumors or hematologic malignancies for whom immunotherapy has regulatory approval or strong Level 1 evidence (e.g., NSCLC, melanoma, bladder cancer, RCC, HCC, MSI-H colorectal cancer, triple-negative breast cancer, classical Hodgkin lymphoma, diffuse large B-cell lymphoma)
• Patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or large B-cell lymphoma who have failed ≥2 prior lines of systemic therapy (CAR-T eligibility)
• ECOG Performance Status 0–2 (patients with PS 3–4 are generally not candidates for aggressive immunotherapy unless performance decline is directly disease-related and reversible)
• Adequate organ function: serum creatinine ≤1.5× ULN, ALT/AST ≤2.5× ULN (≤5× ULN for hepatic metastases), absolute neutrophil count ≥1,500/µL, platelet count ≥75,000/µL
• Confirmed biomarker status via NGS/PD-L1 IHC (TPS/CPS scoring), MSI/MMR testing, TMB quantification, and relevant fusion/mutation profiling (EGFR, ALK, KRAS G12C, BRAF V600E, RET, MET)
• REQUIRED DIAGNOSTIC WORKUP (PRE-TREATMENT):
• Whole-body 18F-FDG PET-CT scan for baseline disease staging and response assessment
• MRI brain with gadolinium contrast (mandatory for lung, melanoma, and breast primaries)
• Multiplex IHC panel: PD-L1 (22C3 or 28-8 assay), CD8+ TIL density, MMR proteins (MLH1, MSH2, MSH6, PMS2)
• Comprehensive genomic profiling (CGP) via FoundationOne CDx, Guardant360, or equivalent next-generation sequencing (NGS) panel
• Echocardiogram (ECHO) and 12-lead ECG (mandatory before checkpoint inhibitor initiation; cardiac toxicity monitoring)
• Pulmonary function tests (PFTs/DLCO) — especially critical before anti-PD-1/PD-L1 agents in patients with pre-existing interstitial lung disease
• Complete metabolic panel, LFTs, TFTs (TSH, free T4), cortisol, HbA1c, and autoimmune antibody screen (ANA, ANCA, anti-dsDNA) to establish endocrine and autoimmune baseline
• Hepatitis B surface antigen, Hepatitis C antibody, and HIV serology (mandatory; HBV reactivation risk with immunotherapy)
• Leukapheresis eligibility assessment (CD3/CD4/CD8 cell counts, Tregs) for CAR-T candidates
• CONTRAINDICATIONS & CAUTIONS:
• Active, systemic autoimmune disease requiring systemic immunosuppression (e.g., active lupus nephritis, severe Crohn's disease, myasthenia gravis) — relative contraindication for checkpoint inhibitors; risk-benefit individualization required
• Prior organ transplantation (solid organ or allogeneic stem cell) — high risk of graft rejection with PD-1/PD-L1 blockade
• Active interstitial lung disease or pneumonitis (grade ≥2) at baseline
• Uncontrolled cardiac arrhythmias or LVEF <40% (impacts CAR-T and cytokine release syndrome [CRS] management capacity)
• Pregnancy or breastfeeding (immunotherapy is teratogenic; reliable contraception mandatory during and for ≥4 months post-treatment)
• Concurrent live vaccine administration (contraindicated during active checkpoint inhibitor therapy)
• Patients requiring chronic high-dose systemic corticosteroids (≥10 mg/day prednisone equivalent) — attenuates immunotherapy efficacy
Procedure
CHECKPOINT INHIBITOR THERAPY (ANTI-PD-1 / PD-L1 / CTLA-4):
This is the most widely deployed immunotherapy modality. Monoclonal antibodies block inhibitory immune checkpoints, releasing cytotoxic T-cell brake mechanisms:
• Anti-PD-1 agents: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Dostarlimab (Jemperli)
• Anti-PD-L1 agents: Atezolizumab (Tecentriq), Durvalumab (Imfinzi), Avelumab (Bavencio)
• Anti-CTLA-4 agents: Ipilimumab (Yervoy), Tremelimumab (Imjudo)
• Dual checkpoint blockade (nivolumab + ipilimumab): Standard of care for metastatic melanoma, MSI-H colorectal cancer, malignant pleural mesothelioma, and selected NSCLC subgroups
• Novel checkpoint targets in clinical use and advanced trials: LAG-3 (relatlimab — FDA-approved in combination with nivolumab for melanoma), TIM-3, TIGIT, VISTA
Administration: IV infusion every 3–6 weeks; most protocols are outpatient-based, with cycle durations of 6 months to 2 years depending on disease response and toxicity profile.
CAR-T CELL THERAPY (CHIMERIC ANTIGEN RECEPTOR T-CELL):
CAR-T is a personalized, living drug requiring apheresis, ex vivo genetic engineering, and lymphodepleting chemotherapy prior to infusion. Currently approved products include:
• Axicabtagene ciloleucel (Yescarta) — CD19-targeting; approved for large B-cell lymphoma and follicular lymphoma
• Tisagenlecleucel (Kymriah) — CD19-targeting; approved for pediatric/young adult ALL and large B-cell lymphoma
• Lisocabtagene maraleucel (Breyanzi) — CD19-targeting; approved for large B-cell lymphoma and CLL
• Idecabtagene vicleucel (Abecma) — BCMA-targeting; approved for relapsed/refractory multiple myeloma
• Ciltacabtagene autoleucel (Carvykti) — BCMA-targeting; approved for multiple myeloma
Process timeline: Leukapheresis → 2–4 weeks manufacturing → lymphodepletion (fludarabine/cyclophosphamide) → CAR-T infusion → 4–7 day inpatient monitoring for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
CRS is graded using ASTCT criteria; severe CRS (Grade ≥3) is managed with tocilizumab (IL-6 receptor blockade) and corticosteroids.
BISPECIFIC T-CELL ENGAGERS (BiTEs) AND BISPECIFIC ANTIBODIES:
Bispecific antibodies simultaneously bind a tumor antigen and CD3 on T cells, forming an immunological synapse that drives tumor cell lysis without prior T-cell sensitization:
• Blinatumomab (Blincyto) — CD19×CD3; approved for B-cell ALL and MRD-positive ALL
• Teclistamab (Tecvayli) — BCMA×CD3; approved for multiple myeloma
• Elranatamab (Elrexfio), Talquetamab (Talvey) — emerging myeloma options
• Mosunetuzumab (Lunsumio) — CD20×CD3; approved for follicular lymphoma
These agents are administered subcutaneously or via continuous IV infusion and require step-up dosing schedules to mitigate CRS risk.
CANCER VACCINES & NEOANTIGEN-BASED IMMUNOTHERAPY:
• Sipuleucel-T (Provenge): Autologous dendritic cell vaccine; approved for metastatic castration-resistant prostate cancer (mCRPC)
• mRNA neoantigen personalized vaccines (e.g., mRNA-4157/V940 in combination with pembrolizumab): Phase 2/3 data in melanoma show significant recurrence-free survival improvement; compassionate access available at select centers
• BCG intravesical therapy: Standard immunotherapy for non-muscle-invasive bladder cancer (NMIBC), administered directly into the bladder post-TURBT
CYTOKINE THERAPIES:
• High-dose IL-2 (aldesleukin): Established in metastatic melanoma and renal cell carcinoma; significant toxicity profile limits use to high-volume centers with dedicated ICU support
• Pegylated IL-2 (bempegaldesleukin): Improved safety profile; in combination trials with nivolumab
• IL-15 superagonist (N-803): Combined with BCG for bladder cancer
ANTIBODY-DRUG CONJUGATES (ADCs) WITH IMMUNOLOGIC MECHANISMS:
• Enfortumab vedotin (Padcev) + pembrolizumab: First-line standard for cisplatin-ineligible advanced urothelial cancer
• Sacituzumab govitecan (Trodelvy): TROP2-targeting; approved for TNBC and urothelial cancer
• Trastuzumab deruxtecan (Enhertu): HER2-targeting; approved for HER2-positive breast, gastric, and HER2-low breast cancers
COMBINATION CHEMOIMMUNOTHERAPY:
Several FDA/EMA-approved regimens combine checkpoint inhibitors with platinum-based chemotherapy to leverage chemotherapy-induced immunogenic cell death:
• Carboplatin/paclitaxel/pembrolizumab (Keynote-789 platform) for metastatic NSCLC
• FOLFOX/FOLFIRI + nivolumab (CheckMate 8HW) for MSI-H/dMMR colorectal cancer
• Gemcitabine/cisplatin + durvalumab (TOPAZ-1) for biliary tract cancers
These regimens require full oncology infusion suite infrastructure with pharmacovigilance protocols for overlapping toxicity management.
Cost of Immunotherapy for Cancer: India vs. UAE
The cost of cancer immunotherapy varies significantly based on the specific agent or combination regimen selected, the number of treatment cycles required, cancer type, and whether advanced modalities such as CAR-T cell therapy are indicated. Both India and the UAE offer access to the same internationally approved immunotherapy drugs and diagnostic technologies; the primary differentiator is cost structure, hospital amenity tier, and geographic accessibility. India offers the most substantial cost advantage — typically 50–70% below US or UK prices — with JCI- and NABH-accredited oncology centers delivering high treatment volumes and specialized expertise. The UAE, particularly Dubai and Abu Dhabi, provides a premium-tier experience with luxury hospital infrastructure, Arabic and multilingual support, and simplified regional access for patients from the Middle East, Africa, and Central Asia, at costs roughly 30–50% below Western markets. For CAR-T cell therapy specifically, both India (limited but growing centers) and the UAE (established CAR-T programs at select JCI hospitals) offer substantially more affordable access than the United States, where CAR-T products alone carry list prices of USD 375,000–465,000 before institutional fees.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $8,000 – $75,000 | ~47% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $18,000 – $140,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-TREATMENT EVALUATION (WEEKS 1–3, OFTEN COMPLETABLE REMOTELY):
• Upload all existing pathology reports, imaging (PET-CT, MRI, CT), surgical/biopsy records, and prior treatment summaries to GAF Healthcare's secure patient portal for remote multidisciplinary tumor board (MDT) review
• GAF Healthcare coordinates an initial teleconsultation with a board-certified medical oncologist specializing in your cancer type within 48–72 hours
• Biomarker testing is arranged: if tissue blocks are available, NGS/CGP and IHC panels are initiated immediately; liquid biopsy (ctDNA) may substitute or supplement if tissue is inadequate
• Baseline organ function labs, cardiac evaluation (ECHO, ECG), and autoimmune/endocrine screening are scheduled upon arrival
• Medical visa (India: e-Medical Visa, processed in 3–5 business days) or UAE entry documentation is arranged by GAF Healthcare's concierge team
PHASE 2 — ARRIVAL AND INSTITUTIONAL WORKUP (DAYS 1–5 IN COUNTRY):
• Airport transfer arranged to partner hospital or designated patient accommodation
• In-person consultation with lead oncologist and MDT; final treatment plan ratified
• Any pending diagnostics completed on-site (PET-CT, MRI brain, PFTs, repeat biopsy if required)
• Treatment consent, pharmacogenomic counseling, and patient/caregiver education session conducted with clinical nurse specialist and GAF Healthcare patient coordinator
• For CAR-T candidates: leukapheresis performed on Day 3–5; cells shipped to manufacturing facility (2–4 week turnaround)
PHASE 3 — TREATMENT INITIATION:
For Checkpoint Inhibitor Therapy:
• Cycle 1 IV infusion administered in the oncology day unit (pembrolizumab: 200 mg over 30 min every 3 weeks; nivolumab: 240 mg over 60 min every 2 weeks — representative examples)
• Patient monitored for 1–2 hours post-infusion for acute infusion reactions
• Immune-related adverse event (irAE) monitoring initiated: daily symptom log, weekly labs (LFTs, TFTs, CBC, CMP) during first cycle
• Cycles 2 and beyond may be administered at a GAF Healthcare partner clinic in the patient's home country or continued at the treating institution
For CAR-T Cell Therapy:
• Day 0: Hospital admission for lymphodepletion chemotherapy (fludarabine 25 mg/m²/day × 3 days + cyclophosphamide 250 mg/m²/day × 3 days)
• Day +1 (after washout): CAR-T cell infusion (single IV administration, typically <30 minutes)
• Days +1 to +7: Mandatory inpatient monitoring in a CRS-capable unit (ICANS-trained nursing staff, tocilizumab and corticosteroids on standby)
• CRS peak onset: Days 2–7 post-infusion; ASTCT Grade ≥3 managed with IL-6 blockade
• ICANS (neurological toxicity) onset: Days 5–14; managed with dexamethasone
• Day +14 to +28: Outpatient follow-up with daily neurological checks and CBC/CMP monitoring
• Day +28 to +30: Response assessment with PET-CT; complete remission confirmed or salvage planning initiated
PHASE 4 — EARLY POST-TREATMENT MONITORING (WEEKS 2–8):
• Endocrine irAE surveillance: thyroid function tests every 6 weeks; cortisol stimulation test if adrenal insufficiency suspected
• Pulmonary: chest CT if new respiratory symptoms develop (pneumonitis is most common Grade 3–4 irAE with anti-PD-1 agents, incidence ~3–5%)
• Dermatologic, gastrointestinal (colitis), and hepatic toxicities managed per ASCO/ESMO irAE management guidelines
• Remote monitoring facilitated via GAF Healthcare's telehealth coordination platform with treating oncologist
FIT-TO-FLY CLEARANCE:
• Checkpoint inhibitor patients: Medically cleared for international flight after completing Cycle 1–2 (typically 3–6 weeks post-treatment initiation) provided no active Grade ≥2 irAEs and stable hemodynamic status
• CAR-T patients: Minimum 4–8 weeks post-infusion before international travel; neurological clearance and B-cell aplasia monitoring (IgG levels) required prior to departure
• Fit-to-fly letter issued by treating oncologist; GAF Healthcare coordinates continuity-of-care documentation package for the patient's home oncologist
PHASE 5 — LONG-TERM FOLLOW-UP:
• Response assessment imaging (PET-CT or CT with contrast) at 8–12 weeks post-initiation
• Treatment continues as per protocol: checkpoint inhibitors typically for 24–35 cycles (2 years) or until disease progression/toxicity
• Ongoing remote MDT review coordinated by GAF Healthcare; option for in-person evaluation cycles at the treating institution at 3–6 month intervals
Risks & Considerations
Cancer immunotherapy carries a distinct and clinically significant toxicity profile that differs fundamentally from conventional chemotherapy. The most consequential category is immune-related adverse events (irAEs), which result from non-specific immune activation affecting normal tissues. Dermatologic irAEs (maculopapular rash, vitiligo, pruritus) occur in 30–40% of patients receiving anti-PD-1 agents and are usually Grade 1–2 and manageable. Endocrinopathies — including hypothyroidism (8–12% incidence), hypophysitis (up to 17% with ipilimumab), and insulin-deficient diabetes mellitus — are frequently permanent and require lifelong hormone replacement despite being otherwise well-tolerated. Immune-mediated pneumonitis (incidence 2.5–5% with anti-PD-1 monotherapy; higher with combination regimens) carries the highest risk of treatment-related mortality and mandates immediate high-dose corticosteroid therapy (methylprednisolone 1–2 mg/kg/day) upon Grade 2 detection. Immune-mediated hepatitis (AST/ALT >3× ULN) occurs in approximately 5–10% of patients on dual checkpoint blockade and may require mycophenolate mofetil or azathioprine if steroid-refractory. For CAR-T therapy, cytokine release syndrome (CRS) affects 42–93% of recipients depending on the product and disease burden; severe CRS (Grade 3–4) occurs in 2–23% and requires ICU-level management with tocilizumab and vasopressor support. Immune effector cell-associated neurotoxicity syndrome (ICANS) manifests as encephalopathy, aphasia, seizures, or cerebral edema in 20–65% of CAR-T recipients; fatal cerebral edema has been reported in <5% of cases. Late-onset irAEs may emerge months to years after checkpoint inhibitor discontinuation, underscoring the need for indefinite endocrine and organ-function surveillance. Patients with pre-existing autoimmune conditions face significantly higher irAE risk and require individualized risk stratification by an experienced clinical immunologist working alongside the treating oncologist. Hyperprogression — paradoxical accelerated tumor growth following PD-1/PD-L1 inhibition — is documented in 10–14% of patients and represents a critical phenomenon requiring early response assessment with PET-CT at 6–8 weeks. Pseudoprogression (apparent radiographic worsening due to immune cell infiltration rather than true disease progression) occurs in approximately 5–10% of responders and should be distinguished from true progression using iRECIST criteria before treatment discontinuation.
Top Hospitals for Immunotherapy for Cancer
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Immunotherapy for Cancer
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Frequently Asked Questions — Immunotherapy for Cancer
The cost of cancer immunotherapy varies considerably depending on the specific agent or combination regimen, the number of treatment cycles required, and whether advanced modalities such as CAR-T cell therapy are part of the protocol. In India, a full course of checkpoint inhibitor therapy (e.g., pembrolizumab every 3 weeks for 6–12 months) typically costs between USD 8,000 and USD 45,000, while CAR-T cell therapy (including leukapheresis, manufacturing logistics, conditioning chemotherapy, infusion, and monitoring) ranges from approximately USD 40,000 to USD 75,000 at leading JCI- and NABH-accredited oncology centers in Mumbai, Delhi, Chennai, and Hyderabad. In the UAE (Dubai and Abu Dhabi), equivalent checkpoint inhibitor protocols range from USD 18,000 to USD 65,000, while CAR-T programs at JCI/DHA-accredited hospitals in Dubai Healthcare City and Abu Dhabi typically range from USD 80,000 to USD 140,000 — still representing a 60–70% cost reduction compared to the United States, where CAR-T product costs alone exceed USD 375,000–465,000 before hospital fees. The cost advantage in India is primarily driven by lower drug acquisition costs (domestic manufacturing of biosimilar checkpoint inhibitors is permitted), lower operational costs, and high treatment volume. The UAE commands a premium reflecting luxury hospital infrastructure, advanced nursing ratios, and geographic convenience for patients from the Middle East, GCC, and Africa. In both destinations, GAF Healthcare provides transparent, itemized cost estimates with no hidden fees before any commitment is made.
The minimum in-country stay required before you are medically cleared for international air travel depends significantly on the specific immunotherapy modality you receive. For checkpoint inhibitor therapy (pembrolizumab, nivolumab, ipilimumab, or combination regimens): The initial workup, biomarker testing, and Cycle 1 administration typically require 2–3 weeks in-country. Once Cycle 1 is complete and no Grade 2 or higher immune-related adverse events (irAEs) are present, most patients receive fit-to-fly clearance after 3–4 weeks total. Subsequent cycles (typically every 3–6 weeks) can often be administered at a GAF Healthcare partner facility closer to your home country. For CAR-T cell therapy: This requires a longer and non-negotiable in-country commitment. After leukapheresis (Day 1), there is typically a 2–4 week wait for cell manufacturing. Lymphodepleting chemotherapy begins 2–3 days before CAR-T infusion. Post-infusion, a minimum of 4 weeks of mandatory inpatient and outpatient monitoring is required to manage cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which can onset up to Day 14. A 28–30 day response assessment PET-CT is performed before discharge planning begins. The minimum realistic total in-country duration for CAR-T patients is 8–10 weeks. For all patients, a formal fit-to-fly letter is issued by the treating oncologist, and GAF Healthcare provides a structured medical summary for cabin crew and customs if required. Long-haul flights carry additional DVT risk in immunocompromised patients, and low-molecular-weight heparin prophylaxis may be recommended depending on thrombotic risk assessment.
The success rate of cancer immunotherapy is highly context-dependent and must be interpreted based on cancer type, molecular biomarker profile, treatment line, and the specific modality used. There is no single universal success rate; the figures below reflect the strongest published clinical data. For PD-1/PD-L1 checkpoint inhibitors in solid tumors: Objective response rates (ORR) range from 15–45% depending on PD-L1 expression and TMB status. In NSCLC with PD-L1 TPS ≥50%, pembrolizumab monotherapy achieves an ORR of approximately 45% and a 5-year overall survival rate of ~31% (Keynote-024 long-term follow-up). In metastatic melanoma treated with dual checkpoint blockade (nivolumab + ipilimumab), 5-year overall survival is approximately 52% (CheckMate 067). Patients with MSI-H/dMMR tumors across any cancer type treated with pembrolizumab or dostarlimab demonstrate ORRs of 40–57%, with a significant subset achieving durable complete responses. For CAR-T cell therapy: In relapsed/refractory large B-cell lymphoma, axicabtagene ciloleucel achieves complete remission rates of 58–73% in the third-line setting, with approximately 40% of patients maintaining response at 24 months. In relapsed/refractory B-cell ALL in pediatric/young adult patients, tisagenlecleucel achieves complete remission in approximately 81% of cases. For multiple myeloma treated with BCMA-targeting CAR-T (ciltacabtagene autoleucel), ORRs exceed 98% with stringent complete response rates of ~73% in heavily pretreated populations. It is essential to understand that 'success' in oncology is measured across multiple endpoints: overall survival, progression-free survival, complete remission, quality of life, and durable disease control. GAF Healthcare's partner oncologists provide individualized probability estimates based on your specific tumor profile, biomarker results, and treatment history during the initial teleconsultation — before any financial or travel commitment is made.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated, end-to-end medical travel coordination service that removes logistical barriers at every stage of the immunotherapy journey, allowing patients and their families to focus entirely on treatment and recovery.
VISA AND ENTRY DOCUMENTATION: For India: GAF Healthcare's dedicated visa concierge team assists patients in applying for the Indian e-Medical Visa, which permits a stay of up to 60 days (extendable) and is typically approved within 3–5 business days. The application requires a formal invitation letter from the treating JCI/NABH-accredited hospital, which GAF Healthcare coordinates directly. Companion/attendant visas (e-Medical Attendant Visa) are processed simultaneously for up to two accompanying family members. For the UAE (Dubai/Abu Dhabi): Citizens of over 50 countries receive visa-on-arrival or visa-free access to the UAE for 30–90 days. Patients from countries requiring advance authorization receive dedicated visa support letters from GAF Healthcare's UAE partner hospitals, facilitating DHA (Dubai Health Authority) or DOH (Abu Dhabi Department of Health) medical treatment entry. UAE long-stay medical visas of up to 3 months can be arranged for CAR-T or extended immunotherapy protocol patients.
AIRPORT AND GROUND TRANSFERS: All patients are met at arrival by a GAF Healthcare patient escort who is aware of their medical condition and any mobility or wheelchair requirements. Private, climate-controlled vehicle transfers are arranged between the airport, hospital, and accommodation for all appointments and discharge. For patients requiring medical-grade transport (supplemental oxygen, stretcher transfer), appropriate vehicles are pre-arranged in coordination with the receiving hospital.
ACCOMMODATION: GAF Healthcare maintains partnerships with serviced apartments and hotels adjacent to all partner oncology centers in India (Mumbai, Delhi NCR, Chennai, Hyderabad, Bangalore) and the UAE (Dubai Healthcare City, Abu Dhabi Medical District). Accommodation options are matched to patient budget and clinical proximity requirements, with priority given to units featuring medical-grade air filtration, kitchen facilities for dietary management, and same-building or walkable access to the treatment facility. Attendant accommodation for one to two family members is arranged at all locations.
MEDICAL COORDINATION AND TRANSLATION: A dedicated GAF Healthcare Patient Coordinator — fluent in the patient's language — is assigned from first contact through final discharge. Translators are available on-site at all partner hospitals for Arabic, Russian, French, Swahili, Uzbek, Kazakh, and other major source-country languages. The coordinator attends all key consultations, communicates daily updates to the patient's family in their home country, and serves as the direct liaison between the treating oncology team and GAF Healthcare's clinical oversight team.
CONTINUITY OF CARE AND TELEMEDICINE: Post-departure, GAF Healthcare maintains a 12-month care coordination relationship. Full medical records, discharge summaries, imaging CDs, pathology blocks, and irAE management protocols are compiled in a structured package translated into English and the patient's preferred language for handover to their home oncologist. Scheduled telemedicine follow-up appointments with the treating oncologist are arranged at 4-week intervals for the first 6 months. Emergency clinical escalation contacts at the treating hospital are provided directly to the patient and their home physician.
Patients Also Explore
Other treatments commonly sought by patients considering Immunotherapy for Cancer.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology